Treatment for irritable bowel syndrome
AssigneeAstellas Pharma Inc.
InventorsRyuichi Takezawa, Hitoshi Doihara, Hiroyuki Ito, Jotaro Suzuki
Life of this patent
Estimating the term…
Abstract
N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide is effective for treating IBS. In addition, IBS may be effectively treated with N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide when used concomitantly with at least one of various serotonin 5-HT3 receptor antagonists.
Claims19
A method for treating IBS, which comprises administering an effective amount of N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide, a pharmaceutically acceptable salt thereof, or a solvate thereof to a patient in need thereof.
A method for treating IBS, which comprises administering an effective amount of N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide, a pharmaceutically acceptable salt thereof, or a solvate thereof and at least one 5-HT3 receptor antagonist to a patient in need thereof.
A composition, comprising:
- (a) N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide, a pharmaceutically acceptable salt thereof, or a solvate thereof;
- and
- (b) at least one 5-HT3 receptor antagonist.
Dependencies are inferred from the claim text.